利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

16 条记录 (耗时 0.023 秒)

    Sustained release pharmaceutical composition
    2.
    发明授权
    Sustained release pharmaceutical composition 失效
    持续释放药物组合物

    公开(公告)号：US5614487A

    公开(公告)日：1997-03-25

    申请号：US69146

    申请日：1993-05-28

    申请人： John E. Battersby ,  Ross G. Clark ,  William S. Hancock

    发明人： John E. Battersby ,  Ross G. Clark ,  William S. Hancock

    IPC分类号： A61K38/27 ,  A61K47/48 ,  A61K38/16

    CPC分类号： A61K38/27 ,  A61K47/4823

    摘要： The present document discloses the formation of imine adducts, preferably between a primary amine of a biologically active polypeptide and a reactive aldehyde group of a physiologically acceptable carrier. The imine adduct of human growth hormone and dextran is specifically described. These adducts serve to release the biologically active polypeptide via the reversible reaction in the formation of the imine adduct bond. These adducts have a surprising degree of stability that permits the use of the complex as a sustained release preparation. A key advantage of this technology is that after hydrolysis the complex releases the unmodified pharmaceutical. Thus, these adducts can be used as pharmaceutical compositions useful for the sustained release of the biologically active polypeptide over a predetermined, desired period of time.

    摘要翻译： 本文件公开了亚胺加成物的形成，优选在生物活性多肽的伯胺和生理上可接受的载体的反应性醛基之间。 具体描述了人生长激素和葡聚糖的亚胺加合物。 这些加合物用于在形成亚胺加合物键时通过可逆反应释放生物活性多肽。 这些加合物具有惊人的稳定性，允许使用复合物作为缓释制剂。 该技术的一个主要优点是水解后，复合物释放出未经修饰的药物。 因此，这些加合物可以用作用于在预定的期望时间段内持续释放生物活性多肽的药物组合物。

    Lipoprotein fractionation
    6.
    发明授权
    Lipoprotein fractionation 失效
    脂蛋白分离

    公开(公告)号：US4603010A

    公开(公告)日：1986-07-29

    申请号：US736306

    申请日：1985-05-21

    申请人： John S. Ayers ,  William S. Hancock ,  David R. K. Harding

    发明人： John S. Ayers ,  William S. Hancock ,  David R. K. Harding

    IPC分类号： C07K14/00 ,  A61K35/14 ,  A61K35/16 ,  A61K38/16 ,  A61M1/36 ,  B01J39/04 ,  B01J47/00 ,  C07K15/16

    CPC分类号： B01J47/003 ,  A61K35/16 ,  B01J39/043

    摘要： A process is described for removing low density and very low density lipoproteins from blood plasma or serum and recovering the plasma or serum in a physiologically acceptable form. The method involves in a preferred embodiment passing plasma or serum through a cationic ion exchanger equilibrated with a physiologically acceptable saline solution. The ion exchanger is a water insoluble hydrophilic, water swellable cross-linked regenerated or microgranular cellulose matrix substituted with hydroxy C.sub.2 -C.sub.4 alkyl group. The ion exchanger capacity is provided by sulphate groups substituted with from 2 to 6 meq/g. The take up of low density lipoproteins is enhanced by recycling the plasma through the column.

    摘要翻译： 描述了从血浆或血清中除去低密度和极低密度脂蛋白的方法，并以生理上可接受的形式回收血浆或血清。 该方法包括在优选实施方案中使血浆或血清通过用生理学上可接受的盐水溶液平衡的阳离子离子交换剂。 离子交换剂是由羟基C 2 -C 4烷基取代的水不溶性亲水性，水溶胀性交联的再生或微粒状纤维素基质。 离子交换容量由2〜6meq / g取代的硫酸盐基团提供。 低密度脂蛋白的吸收通过将血浆循环通过柱来增强。

    Activated matrix and method of activation
    8.
    发明授权
    Activated matrix and method of activation 失效
    活化基质和活化方法

    公开(公告)号：US4330440A

    公开(公告)日：1982-05-18

    申请号：US128847

    申请日：1980-03-10

    申请人： John S. Ayers ,  Geoffrey S. Bethell ,  William S. Hancock ,  Milton T. W. Hearn

    发明人： John S. Ayers ,  Geoffrey S. Bethell ,  William S. Hancock ,  Milton T. W. Hearn

    IPC分类号： C08B15/06 ,  C08B37/00 ,  C12N11/10 ,  G01N33/543 ,  G01N33/548 ,  C08L1/00

    CPC分类号： G01N33/548 ,  C08B15/06 ,  C08B37/0039 ,  C12N11/10 ,  G01N33/54353

    摘要： The invention relates to the carbonylation of cross linked substituted and unsubstituted polysaccharides, their copolymers with macroporous synthetic polymers, macroporous synthetic polymers and rigid supports with pendant hydroxyalkyl groups. The carbonylated product can be used to prepare an affinity chromatography matrix which remains an uncharged species at varying pH's. The carbonylated product is also useful for the preparation of other compounds: Typical polysaccharides are agarose, starch, dextran, cellulose and regenerated cellulose, typical macroporous synthetic polymers are acrylamides, acrylates and methacrylates, typical rigid supports are silica beads coated with hydroxy alkyl groups and typical cabonylating agents are N,N'-carbonyl diimidazole; N,N'carbonyl di-1,2,3-benzotriazole; and N,N'-carbonyl di-1,2,4-triazole.

    摘要翻译： 本发明涉及交联的取代和未取代的多糖，它们与大孔合成聚合物的共聚物，大孔合成聚合物和具有侧羟基烷基的刚性载体的羰基化。 羰基化产物可用于制备在不同pH值下保持不带电荷的物质的亲和层析基质。 羰基化产物也可用于制备其他化合物：典型的多糖是琼脂糖，淀粉，葡聚糖，纤维素和再生纤维素，典型的大孔合成聚合物是丙烯酰胺，丙烯酸酯和甲基丙烯酸酯，典型的刚性载体是用羟基烷基涂覆的二氧化硅珠， 典型的卡罗胺化剂是N，N'-羰基二咪唑; N，N'-羰基二-1,2,3-苯并三唑; 和N，N'-羰基二-1,2,4-三唑。

    Monoclonal antibody based biomarker discovery and development platform
    9.
    发明授权
    Monoclonal antibody based biomarker discovery and development platform 有权
    基于单克隆抗体的生物标志物发现和开发平台

    公开(公告)号：US08512959B2

    公开(公告)日：2013-08-20

    申请号：US10588392

    申请日：2005-02-09

    申请人： Laszlo Takacs ,  Andras Guttman ,  William S. Hancock ,  Barry L. Karger ,  Manuel Duval ,  Patrick Berna

    发明人： Laszlo Takacs ,  Andras Guttman ,  William S. Hancock ,  Barry L. Karger ,  Manuel Duval ,  Patrick Berna

    IPC分类号： G01N33/53

    CPC分类号： G01N33/6854 ,  B01L3/5027 ,  C07K16/18 ,  G01N33/54386 ,  G01N33/577 ,  G01N33/6845 ,  G01N2500/00

    摘要： A method or platform for monoclonal antibody based biomarker discovery is disclosed. The method according to the invention provides for the integration of analyte collection, hybridoma screening and nanovolume integrated mass spectrometry (NVIMS) to achieve a robust screening system that is capable, for example, of cutting 4-6 years off of the classical biomarker discovery and development process. The invention provides a platform for the rapid, high-throughput production, isolation and characterization of, e.g., disease specific biomarkers together with highly specific monoclonal antibodies. The method of the invention has a variety of applications such as, but not limited to, drug testing, biohazard applications, ecological applications, physiological applications and/or pathology screening applications. The method of the invention is also capable of being performed or used as or with a high-throughput screening process or system of the invention.

    摘要翻译： 公开了用于基于单克隆抗体的生物标志物发现的方法或平台。 根据本发明的方法提供了分析物收集，杂交瘤筛选和纳瓦级综合质谱（NVIMS）的整合，以实现强大的筛选系统，其能够例如从经典生物标志物发现开始4-6年， 开发过程。 本发明提供了用于快速，高通量生产，分离和表征例如疾病特异性生物标志物以及高度特异性单克隆抗体的平台。 本发明的方法具有多种应用，例如但不限于药物测试，生物危害应用，生态应用，生理应用和/或病理学筛选应用。 本发明的方法还能够作为或与本发明的高通量筛选方法或系统一起使用或使用。